Newport Laboratories is now part of Boehringer Ingelheim
DULUTH, Ga. — [June 12, 2018]
Boehringer Ingelheim (BI) is excited to announce that Newport Laboratories, Inc. in Worthington, Minnesota, is officially part of Boehringer Ingelheim’s animal health business unit.
Newport Laboratories enhances the service and product offerings for BI customers. By providing cutting-edge diagnostics like whole genome sequencing, metagenomics, and bioinformatics, Newport Laboratories crafts custom, autogenous vaccines that target the specific viruses or bacteria causing disease in individual livestock operations.
“Joining the BI family helps strengthen Newport Laboratories’ overall offering of disease-prevention products and diagnostic tests,” says Edgar Diaz, DVM, MS, president of Newport Laboratories. “Newport Laboratories is a great fit because we can enhance the protection that BI’s already robust line of vaccines offers to swine and cattle producers. With a focus on customer service and relationships that are at the core of who we are at Newport Laboratories, it’s refreshing to have the support of a larger company that shares those values.”
With solutions from both Newport Laboratories and Boehringer Ingelheim Health Management Center (HMC), which offers both diagnostic testing and field research services, BI now provides customers one of the most complete disease-prevention toolboxes in the livestock industry.
“Working together gives BI, Newport Laboratories and HMC the ability to give our customers a more well-rounded and comprehensive portfolio of products,” says Del Birkhofer, head of Boehringer Ingelheim’s U.S. Swine Business and Newport Laboratories. “We are now able to offer a broader range of animal health solutions, more resources, greater expertise and more innovation than we were even 18 months ago.”
About Boehringer Ingelheim Animal Health
As the second largest animal health business in the world, Boehringer Ingelheim is committed to improving animal health. With more than 10,000 employees worldwide, Boehringer Ingelheim Animal Health has products available in more than 150 markets and a global presence in 99 countries. For more information about Boehringer Ingelheim Animal Health, click here.
About Newport Laboratories
Newport Laboratories, Inc., is a Boehringer Ingelheim company and the nation's leading manufacturer of custom made vaccines. Located in Worthington, Minnesota, Newport Laboratories assists veterinarians and livestock producers in their efforts to address animal health problems through cutting edge diagnostic testing and production of high-quality, evidence-based, custom made vaccines. For further information call 800-220-2522, email firstname.lastname@example.org or visit the Newport Laboratories website at http://www.newportlabs.com.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the industry’s top 20 pharmaceutical companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas of human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. In 2016, Boehringer Ingelheim achieved net sales of around 15.9 billion euros. With more than three billion euros, R&D expenditure corresponds to 19.6 per cent of net sales.
Social responsibility comes naturally to Boehringer Ingelheim. That is why the company is involved in social projects, such as the “Making More Health” initiative. Boehringer Ingelheim also actively promotes workforce diversity and benefits from its employees’ different experiences and skills. Furthermore, the focus is on environmental protection and sustainability in everything the company does.
PR Account Supervisor
Heidi De Wit-Sommerfeld
Boehringer Ingelheim Animal Health - U.S. Communications